Tag: biologic drug switch

Switching from an originator biologic to a biosimilar is safe for most patients with stable chronic conditions. Evidence shows no meaningful difference in efficacy or safety, though psychological factors can affect perception. Cost savings are significant, and structured patient communication improves outcomes.

Recent-posts

JAK Inhibitors: What Infections and Blood Clots to Watch For

Jan, 16 2026

Biosimilar Switching: What Happens When You Change from Originator

Feb, 1 2026

Alzheimer’s Disease Guide: Memory Loss, Progression, and 2026 Treatments

Apr, 24 2026

Antihypertensive Combination Generics: What’s Available and How to Get It

Feb, 20 2026

Pharmacy Margin Economics: How Generics Drive Profits in Today’s Drug Market

Dec, 15 2025